Melanotan II vs Telmisartan
Well Studied vs FDA Approved
monitor Mechanism-based · 51% Both Melanotan II and Telmisartan can raise blood pressure. Monitor BP regularly and consider adding cardiovascular support (cardarine, telmisartan, or similar).
Molecular Data
Melanotan II Telmisartan
Weight — 514.62 Da
Half-life ~2 hours ~24 hours
Type Synthetic alpha-MSH analog Benzimidazole derivative (C33H30N4O2)
Key Benefits
Melanotan II
01 Rapid tanning without UV exposure
02 Enhanced sexual function and libido
03 Appetite suppression
04 Improved mood via melanocortin activation
05 Photoprotection through increased melanin
Telmisartan
01 Potent 24-hour blood pressure reduction with once-daily dosing
02 Protection against AAS-induced left ventricular hypertrophy and cardiac remodeling
03 Nephroprotection through reduced intraglomerular pressure and proteinuria
04 Unique partial PPAR-gamma agonism improving insulin sensitivity and lipid metabolism
05 No negative impact on exercise performance, VO2 max, or recovery
06 Reduction of pathological vascular remodeling and arterial stiffness
07 Longest half-life of all ARBs ensuring consistent 24-hour coverage
08 Well-tolerated with a low incidence of side effects compared to ACE inhibitors (no dry cough)
Dosing Protocols
Melanotan II
Loading: Start 0.25mg daily, increase to 0.5-1mg; Maintenance: 0.5-1mg 2-3x weekly / Loading phase: Daily for first week, then tanning maintenance 2-3x weekly or as needed for sexual enhancement
Initial loading phase 0.25mg 1x daily
Tanning maintenance 0.5-1mg 2-3x weekly
Sexual enhancement 0.5-1mg As needed
Minimal side effects 0.1-0.25mg Every other day
Photoprotection 0.5mg 2x weekly
Telmisartan
20-80 mg/day / Once daily
Side Effects
Melanotan II
Nausea (pre-treatment with antiemetics recommended)
Facial flushing
Temporary blood pressure elevation
Fatigue
Spontaneous erections
Telmisartan
Dizziness or lightheadedness, particularly during the first few days or after dose increases
Mild hypotension, especially in volume-depleted individuals or those on concurrent antihypertensives
Upper respiratory tract infection symptoms (sinusitis, pharyngitis) - reported in clinical trials at rates similar to placebo
Back pain and myalgia (uncommon but reported)
Fatigue
Contraindications
History of melanoma or dysplastic nevi
Pregnancy or breastfeeding
Cardiovascular conditions
Uncontrolled hypertension
Pregnancy (Category D - can cause fetal injury and death; discontinue immediately if pregnancy is detected)
Bilateral renal artery stenosis
Known hypersensitivity to telmisartan or any excipients
Concurrent use with aliskiren in patients with diabetes or renal impairment (eGFR <60)
Severe hepatic impairment or biliary obstruction (telmisartan is eliminated primarily via biliary excretion)
Research Evidence
Melanotan II Telmisartan
Status Well Studied FDA Approved
References 4 studies 5 studies
Latest 2024 2023
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.